TY - JOUR
T1 - Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse
AU - Jain, Preetesh
AU - Kantarjian, Hagop
AU - Patel, Keyur
AU - Faderl, Stefan
AU - Garcia-Manero, Guillermo
AU - Benjamini, Ohad
AU - Borthakur, Gautam
AU - Pemmaraju, Naveen
AU - Kadia, Tapan
AU - Daver, Naval
AU - Nazha, Aziz
AU - Luthra, Raja
AU - Pierce, Sherry
AU - Cortes, Jorge
AU - Ravandi, Farhad
PY - 2014/6
Y1 - 2014/6
N2 - Patients with newly diagnosed AML (n = 360) including 137 (38%) with normal karyotype (NK) were evaluated. Overall, 60 (16.6%) patients, including 46 of the 137 (33.5%) NK patients, had NPM1 mutation at baseline. Thirty-nine patients (30 NK) had available NPM1 status at the time of complete remission (CR) and all (100%) were negative for mutated NPM1. Among the patients with mutated NPM1 at baseline, 10/39 overall (25%) and 7/30 NK (23%) patients relapsed. NPM1 status was available for eight patients (six with NK) at the time of relapse. Among them, 7/8 overall (87%) and 5/6 NK (83%) patients had mutated NPM1, while 1/8 overall (12%) and 1/6 NK (16%) patients remained NPM1 wild type. Among the 300 patients (including 91 with NK) with wild type NPM1 at diagnosis, none acquired a mutated NPM1 clone, either at CR or at relapse. We conclude that mutated NPM1 is a stable and reliable prognostic marker in AML and can be used to assess MRD.
AB - Patients with newly diagnosed AML (n = 360) including 137 (38%) with normal karyotype (NK) were evaluated. Overall, 60 (16.6%) patients, including 46 of the 137 (33.5%) NK patients, had NPM1 mutation at baseline. Thirty-nine patients (30 NK) had available NPM1 status at the time of complete remission (CR) and all (100%) were negative for mutated NPM1. Among the patients with mutated NPM1 at baseline, 10/39 overall (25%) and 7/30 NK (23%) patients relapsed. NPM1 status was available for eight patients (six with NK) at the time of relapse. Among them, 7/8 overall (87%) and 5/6 NK (83%) patients had mutated NPM1, while 1/8 overall (12%) and 1/6 NK (16%) patients remained NPM1 wild type. Among the 300 patients (including 91 with NK) with wild type NPM1 at diagnosis, none acquired a mutated NPM1 clone, either at CR or at relapse. We conclude that mutated NPM1 is a stable and reliable prognostic marker in AML and can be used to assess MRD.
KW - AML
KW - MRD
KW - Minimal residual disease
KW - NPM1 mutations
UR - http://www.scopus.com/inward/record.url?scp=84901335895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901335895&partnerID=8YFLogxK
U2 - 10.3109/10428194.2013.840776
DO - 10.3109/10428194.2013.840776
M3 - Article
C2 - 24004182
AN - SCOPUS:84901335895
SN - 1042-8194
VL - 55
SP - 1337
EP - 1344
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -